Pyrotinib-assisted whole brain radiotherapy alleviates HER2-positive advanced breast cancer and brain metastases: a prospective study in patients.

ABSTRACT:

Purpose

The whole-brain radiotherapy (WRBT)-based therapeutic efficacy is often limited against human epidermal growth factor receptor 2 (HER2+)-positive advanced breast cancer (BC) and brain metastases (BM), requiring more effective treatment options. This prospective study evaluates the effectiveness and safety of combining WBRT with pyrotinib in patients with HER2+ advanced BC and BM.

Methods

The enrolled patients (n = 26, from April 2019 to March 2022) were divided into two treatment groups. Group 1 (p-WBRT) received pyrotinib initially, followed by subsequent WBRT. Group 2 (WBRT-p) received WBRT concurrently with pyrotinib. The intracranial progression-free survival (iPFS) was determined.

Results

In the WBRT-p group (n = 11), the median iPFS was rec

SUBMITTER: Zhou F 

PROVIDER: S-EPMC11868727 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature